Literature DB >> 33215272

Metabolic syndrome in women with and without interstitial cystitis/bladder pain syndrome.

Liao Peng1, Xing-Peng Di1, Shi-Xin He2, Xiao Zeng1, Hong Shen1, Hui-Li Zhu3, De-Yi Luo4.   

Abstract

INTRODUCTION AND HYPOTHESIS: The aim of this study was to compare the frequency of metabolic syndrome (MetS) in patients with and without interstitial cystitis/bladder pain syndrome (IC/BPS).
METHODS: This case-control study evaluated the indicators of MetS in 287 females with IC/BPS and in 287 females without IC/BPS in West China Hospital between January 2010 and January 2020. Then, the number of voids per day, frequency of night urination, O'Leary-Sant Interstitial Cystitis Symptom/Problem Index, and visual analog scale were examined in the two groups.
RESULTS: Based on both the National Cholesterol Education Program Adult Treatment Panel III recommendations and the International Diabetes Federation criteria, the distribution of MetS was statistically higher in patients with IC/BPS than in the control group, with 34.8% vs 17.8% (P < 0.0001) and 34.2% vs 20.9% (P = 0.0005), respectively. Regarding symptom scores, the IC/BPS group demonstrated significantly higher scores than the control group in all aspects (P < 0.0001). More patients with anxiety (P < 0.0001), insomnia (P < 0.0001), hypertension (P = 0.0001), and diabetes mellitus (P = 0.017) were observed in the IC/BPS group. Moreover, the findings indicated that patients with IC/BPS had a higher BMI (P = 0.0001) and larger waist circumference (P = 0.0001). Blood tests presented a significantly higher level of fasting glycemia, serum cystatin-C, and triglycerides in patients with IC/BPS. Furthermore, higher ORs for the occurrence of MetS among cases were observed, although this was not statistically significant.
CONCLUSIONS: MetS frequency was relatively high in patients with IC/BPS. Further research is needed to understand the common pathophysiologic mechanism of IC/BPS and MetS.

Entities:  

Keywords:  Body mass index; Interstitial cystitis/bladder pain syndrome; Metabolic syndrome; Obesity

Year:  2020        PMID: 33215272     DOI: 10.1007/s00192-020-04605-w

Source DB:  PubMed          Journal:  Int Urogynecol J        ISSN: 0937-3462            Impact factor:   2.894


  30 in total

1.  Prevalence and correlates for interstitial cystitis symptoms in women participating in a health screening project.

Authors:  Christian Temml; Clemens Wehrberger; Claus Riedl; Anton Ponholzer; Martin Marszalek; Stephan Madersbacher
Journal:  Eur Urol       Date:  2006-08-30       Impact factor: 20.096

2.  Metabolic syndrome in female patients with overactive bladder.

Authors:  Hakkı Uzun; Orhan Ünal Zorba
Journal:  Urology       Date:  2011-10-19       Impact factor: 2.649

3.  Impact of metabolic syndrome on stress urinary incontinence in pre- and postmenopausal women.

Authors:  Alper Otunctemur; Murat Dursun; Emin Ozbek; Suleyman Sahin; Huseyin Besiroglu; Ismail Koklu; Mustafa Erkoc; Eyyup Danis; Muammer Bozkurt
Journal:  Int Urol Nephrol       Date:  2014-03-04       Impact factor: 2.370

4.  Is there an association between aspects of the metabolic syndrome and overactive bladder? A prospective cohort study in women with lower urinary tract symptoms.

Authors:  M M Zacche; I Giarenis; G Thiagamoorthy; D Robinson; L Cardozo
Journal:  Eur J Obstet Gynecol Reprod Biol       Date:  2017-08-02       Impact factor: 2.435

Review 5.  Pharmacological management of interstitial cystitis /bladder pain syndrome and the role cyclosporine and other immunomodulating drugs play.

Authors:  Teruyuki Ogawa; Osamu Ishizuka; Tomohiro Ueda; Pradeep Tyagi; Michael B Chancellor; Naoki Yoshimura
Journal:  Expert Rev Clin Pharmacol       Date:  2018-04-09       Impact factor: 5.045

6.  The impact of Diabetes Mellitus on Lower urinary tract symptoms (LUTS) in both male and female patients.

Authors:  Efstathios Papaefstathiou; Kyriakos Moysidis; Pavlos Sarafis; Evaggelos Ioannidis; Konstantinos Hatzimouratidis
Journal:  Diabetes Metab Syndr       Date:  2018-11-03

7.  Bridging pharmacotherapy and minimally invasive surgery in interstitial cystitis/bladder pain syndrome treatment.

Authors:  Athanasios E Dellis; Athanasios G Papatsoris
Journal:  Expert Opin Pharmacother       Date:  2018-08-03       Impact factor: 3.889

Review 8.  Diagnostic criteria, classification, and nomenclature for painful bladder syndrome/interstitial cystitis: an ESSIC proposal.

Authors:  Joop P van de Merwe; Jørgen Nordling; Pierre Bouchelouche; Kirsten Bouchelouche; Mauro Cervigni; L Kurosch Daha; Suzy Elneil; Magnus Fall; Gero Hohlbrugger; Paul Irwin; Svend Mortensen; Arndt van Ophoven; John L Osborne; Ralph Peeker; Benedikte Richter; Claus Riedl; Jukka Sairanen; Martina Tinzl; Jean-Jacques Wyndaele
Journal:  Eur Urol       Date:  2007-09-20       Impact factor: 20.096

9.  Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity.

Authors:  K G M M Alberti; Robert H Eckel; Scott M Grundy; Paul Z Zimmet; James I Cleeman; Karen A Donato; Jean-Charles Fruchart; W Philip T James; Catherine M Loria; Sidney C Smith
Journal:  Circulation       Date:  2009-10-05       Impact factor: 29.690

Review 10.  Pathomechanism of Interstitial Cystitis/Bladder Pain Syndrome and Mapping the Heterogeneity of Disease.

Authors:  Jia-Fong Jhang; Hann-Chorng Kuo
Journal:  Int Neurourol J       Date:  2016-11-22       Impact factor: 2.835

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.